Home › Fibromyalgia › NCT06866444

Duloxetine Metabolism and Fibromyalgia

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults 18+
* Meeting diagnostic criteria for Fibromyalgia
* Patients taking Duloxetine 60 mg/day for at least 8 weeks

Exclusion Criteria:

* Pregnant patients per verbal confirmation
* Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis.
* Patients requiring an interpreter to communicate
* Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).

About the study

People with fibromyalgia report generalized body pain ("pain all over"), increased sensitivity to painful stimulation, chronic tiredness or low energy, sleep problems, and other physical and functional problems. The exact cause of the disorder is poorly understood, and treatment can be difficult.

The degree to which duloxetine is helpful for people with fibromyalgia varies greatly. For some people, it is very helpful for managing fibromyalgia symptoms. For others, people may not notice any benefit. Yet for some, it is a little helpful and the effect is noticeable only when people forget to take the medicine.

The purpose of this study is to collect data to better understand the relationship among gene types that control those enzymes, blood concentrations of duloxetine, and how it helps the symptoms.

What is being tested

• Observational (drug)

Sponsor: University of Utah · Participants: 100 · Started: May 1, 2025

Contact the study team

• Jake Steenblick, DNP · Phone: 801-585-1216
• Natalie R Bennion, MPH · Phone: 801-585-7697

Official record on ClinicalTrials.gov — NCT06866444

Locations in the U.S.

Conditions

• Fibromyalgia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.